← Back to Search

Anti-VEGF

SCD411 for Age-Related Macular Degeneration

Phase 3
Waitlist Available
Research Sponsored by Sam Chun Dang Pharm. Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 4, 8, 20, 36 and 52
Awards & highlights

Summary

This trial is testing SCD411, a new drug similar to Eylea, in adults with wet age-related macular degeneration (AMD). Wet AMD causes vision loss due to abnormal blood vessels growing and leaking in the eye. SCD411 works by blocking a protein that causes these harmful blood vessels to grow and leak. The study will check if SCD411 is as safe and effective as Eylea.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 4, 8, 20, 36 and 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 4, 8, 20, 36 and 52 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Percentage of Subjects With Anti-SCD411 Antibodies

Side effects data

From 2022 Phase 3 trial • 576 Patients • NCT04480463
7%
Neovascular age-related macular degeneration
6%
COVID-19
4%
Visual acuity reduced
4%
Hypertension
3%
Back pain
3%
Urinary tract infection
2%
Vitreous floaters
2%
Nasopharyngitis
2%
Type 2 diabetes mellitus
2%
Dry eye
2%
Osteoarthritis
2%
Abdominal pain
2%
Intraocular pressure increased
2%
Conjunctivitis
1%
Sinusitis
1%
Arthralgia
1%
Atrial fibrillation
1%
Age-related macular degeneration
1%
Posterior capsule opacification
1%
Sleep apnoea syndrome
1%
Tooth abscess
1%
Cataract
1%
Gastroenteritis
1%
Eye pain
1%
Punctate keratitis
1%
Subretinal fluid
1%
Pneumonia
1%
Dyspepsia
1%
Pain in extremity
1%
Lacrimation increased
1%
Visual impairment
1%
Retinal pigment epithelial tear
1%
Conjunctival haemorrhage
1%
Dizziness
1%
Headache
1%
Cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
SCD411
Aflibercept

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SCD411Experimental Treatment1 Intervention
Group II: AfliberceptActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SCD411
2020
Completed Phase 3
~580

Find a Location

Who is running the clinical trial?

Sam Chun Dang Pharm. Co. Ltd.Lead Sponsor
Byung Jhip HaStudy DirectorSam Chun Dang Pharm. Co. Ltd.
~113 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top